meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced RCC (mRCC) - 1st line (L1)
11
mRCC - L1 - PDL1 negative
1
mRCC - L1 - PDL1 positive
4
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
atezolizumab plus bevacizumab
avelumab based treatment
avelumab plus axitinib
versus all
vs VEGF(R) inhibitor
vs sunitinib
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
Study
Exclusion reasons
Remarks
Reference(s)
Empty list - no studies excluded